Paolo Prandoni

Posts

Risk of thromboembolism in cancer patients with Port-a-Cath. Results and implications of the ONCOCIP study
Risk Factors

Risk of thromboembolism in cancer patients with Port-a-Cath. Results and implications of the ONCOCIP study

The normal experience of cancer patients who receive an implantable venous access device (Port-a-Cath) for chemotherapy infusion is not well known, nor have the risk factors associated with thromboembolism been appropriately investigated.

Read More
Lessons from the CATCH study: beware of the risk of bleeding in neoplastic patients treated for VTE
Trial Update

Lessons from the CATCH study: beware of the risk of bleeding in neoplastic patients treated for VTE

The results of an interesting secondary analysis of the CATCH study were published recently and they are useful for a better understanding of the expectations and risks associated with the use of anticoagulants for the treatment of VTE in cancer patients.

Read More
New perspectives for the treatment of cancer-associated thrombosis
Anticoagulation Drugs

New perspectives for the treatment of cancer-associated thrombosis

Patients with cancer-associated thrombosis (CAT) exhibit a risk of venous thromboembolic (VTE) complications, which exceeds by far those expected in the general population, and prevail in patients with the most advanced stages of cancer

Read More